Will the Catholic Church & U.S. Courts embrace Advanced Cell Technology “Embryo-Safe” technique?

Advanced Cell Technology (OTC:ACTC) with laboratory facilities in Massachusetts has pioneered a solution to the ethical, moral & legal debate surrounding human embryonic stem cell research. ACT has developed the “single-blastomere” technique. Patent Number 7,893,315 a non-destructive alternative for deriving human embryonic stem cell (hESC) lines.

Online PR News – 15-May-2011 – – This achievement in Regenerative medicine is a ground breaking feat for both Catholic, U.S. and EU law.

• The 1995 encyclical The Gospel of Life, of which Pope John Paul II wrote: "Human embryos obtained in vitro are human beings and are subjects with rights; their dignity and right to life must be respected from the first moment of their existence. It is immoral to produce human embryos destined to be exploited as disposable 'biological material'" (1,5 )

• The Dickey Amendment (also known as the Dickey-Wicker Amendment) is the name of an appropriation bill rider attached to a bill passed by United States Congress in 1995, and signed by former President Bill Clinton, which prohibits the Department of Health and Human Services (HHS) from using appropriated funds for the creation of human embryos for research purposes or for research in which human embryos are destroyed.

“The study results of ACT’s RPE cells implanted in the various animal models of macular degeneration was phenomenal. If ACT observes even a fraction of that benefit in humans, it will be nothing short of a home run."

• Outside scope of federal court’s original injunction in Sherley vs.Sebelius (U.S.)

• Advocate General Yves Bot opinion to Court of Justice in Brüstle vs. Greenpeace (Europe).
The single-blastomere technology uses a one-cell biopsy approach similar to pre-implantation genetic diagnosis (PGD), which is widely used in the in vitro fertilization (IVF) process and does not interfere with the embryo’s developmental potential. The safety record for one-cell biopsy as part of PGD now has a 15-year track record, and is carried out routinely as part of IVF processes around the world.

ACT’s (SCB) technique can be paralleled in its use as a blood transfusion, but on a molecular level. In a traditional blood transfusion 1 pint yields trillions of red blood cells. ACT’s “embryo-safe” technique extracts just one cell from 2 day old embryo. As the human body regenerates the trillions of red blood cells removed, so does the 2 day old embryo regenerates the one missing cell making the human embryo as it was prior. ACT researchers have found that not only does the (SCB) technique solve the ethical concerns but as an added benefit the (hESC) extracted at such an early growth stage of the embryo are more robust and reproducible than traditional ICM derived lines. In a Head-to-head comparison with 24 NIH lines average 5X more efficient than the best NIH lines for producing cells from all three germ layers.

Advanced Cell Technology is moving forward using the (SCB) technique in a US Food and Drug Administration (FDA) a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic Stem Cells for both Stargardt’s Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD) the most common form of macular degeneration in the world affecting an estimated 150 million people. The trial will take place at UCLA’s Jules Stein Eye Institute in California.

Raymond Lund, Ph.D., a scientific collaborator with ACT, and considered one of the world’s foremost experts in retinal cell physiology and vision restoration, commented, “The study results of ACT’s RPE cells implanted in the various animal models of macular degeneration was phenomenal. If ACT observes even a fraction of that benefit in humans, it will be nothing short of a home run."

The rare occurrence of a quantum leap shows itself to the world on average 2 times a decade. Regenerative medicine just maybe the 1st quantum leap in the 21st century.

Disclosure: Stem Cell Media LLC nor its Companies was compensated by “any” entity for this article. www.investorstemcell.com is bringing investors and stakeholders together to participate in the world’s only online discussion forum dedicated to regenerative medicine. A paradigm shift in health care is upon the world.

Visit Our Site
Contact Information
Sai Rosen
Stem Cell Media LLC


Share and Connect